Cutaneous squamous cell carcinoma (SCC), along with basal cell carcinoma (BCC), comprise the non-melanoma skin cancers (NMSC), the most common cancer in Caucasians, with more than 3,000,000 new cases diagnosed annually in the United States. While not usually fatal, SCC may repeatedly recur and result in death in a small proportion of patients, and a history of SCC has been consistently associated with an increased risk of several other types of cancers. Despite the current knowledge about the harms of sun exposure, and increased use of sunscreen, SCC incidence rates continue to increase, emphasizing the public health importance of this highly prevalent cancer, and highlighting the need for an increased understanding of its etiology and control. Accumulating evidence suggests that cutaneous human papillomavirus (HPV) infection may be a risk factor for developing NMSC, particularly SCC. DNA from cutaneous HPV types in multiple genera has been detected in up to 50% of SCC tissues from immuno-competent individuals. In addition, several case-control studies have demonstrated statistically significant associations between SCC and antibodies against cutaneous HPV types, presence of HPV DNA in eyebrow hair follicles or HPV DNA in normal skin samples. Tumor-based HPV DNA detection and serology measurements were incorporated into our own case-control study, in which cutaneous HPV seroreactivity was significantly associated with HPV DNA-positive SCC, with antibodies detected for the same HPV types that were present in the tumor tissue. In the same study, SCC was also associated with another cutaneous virus, Merkel cell polyomavirus (MCV), with MCV DNA-positive cases having significantly higher MCV antibody levels than controls. Although the case-control data are highly compelling, causal associations between cutaneous papillomavirus and polyomavirus infections cannot be established in the absence of prospective data that clearly demonstrate the presence of the viral infections prior to the onset of disease. We propose to conduct a prospective cohort study of individuals at risk for SCC, obtaining multiple biospecimens for the measurement of cutaneous HPV and MCV infections, and following participants for up to four years, conducting full body skin exams for the detection of incident SCC. The goal of the proposed research is to estimate the risk of SCC associated with cutaneous HPV and MCV infections and to demonstrate type-specific concordance between viral infections in normal tissues and subsequent NMSC lesions. The proposed study would provide the critical evidence needed for establishing causality between cutaneous viral infections and SCC.

Public Health Relevance

We hypothesize that an increased risk of squamous cell carcinoma (SCC) will be observed among individuals infected with cutaneous HPV and MCV, and that the same viral types present in normal tissues will be detected in the subsequent SCC tumors. The proposed study would provide the critical temporal evidence for the design and eventual implementation of potential vaccination strategies aimed at reducing incidence of SCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA168536-01A1
Application #
8556444
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
2013-09-20
Project End
2018-07-31
Budget Start
2013-09-20
Budget End
2014-07-31
Support Year
1
Fiscal Year
2013
Total Cost
$297,619
Indirect Cost
$120,991
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Freeman-Keller, Morganna; Kim, Youngchul; Cronin, Heather et al. (2016) Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. Clin Cancer Res 22:886-94
Pilon-Thomas, Shari; Kodumudi, Krithika N; El-Kenawi, Asmaa E et al. (2016) Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy. Cancer Res 76:1381-90
Smalley, Keiran S M; Fedorenko, Inna V; Kenchappa, Rajappa S et al. (2016) Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy. Int J Cancer 139:1195-201
Prieto-Granada, Carlos N; Wiesner, Thomas; Messina, Jane L et al. (2016) Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST. Am J Surg Pathol 40:479-89
Emmons, Michael F; Faião-Flores, Fernanda; Smalley, Keiran S M (2016) The role of phenotypic plasticity in the escape of cancer cells from targeted therapy. Biochem Pharmacol 122:1-9
Smalley, Keiran S M; Eroglu, Zeynep; Sondak, Vernon K (2016) Combination Therapies for Melanoma: A New Standard of Care? Am J Clin Dermatol 17:99-105
Sung, Hyeran; Kanchi, Krishna L; Wang, Xue et al. (2016) Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation. Oncotarget 7:23885-96
Fedorenko, I V; Abel, E V; Koomen, J M et al. (2016) Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene 35:1225-35
Nemoto, Satoshi; Mailloux, Adam W; Kroeger, Jodi et al. (2016) OMIP-031: Immunologic checkpoint expression on murine effector and memory T-cell subsets. Cytometry A 89:427-9
Woan, K V; Lienlaf, M; Perez-Villaroel, P et al. (2015) Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation. Mol Oncol 9:1447-57

Showing the most recent 10 out of 33 publications